NASDAQ:GTHX

G1 Therapeutics (GTHX) Stock Forecast, Price & News

$1.44

+0.09 (+6.67%)

(As of 09/29/2023 ET)

Compare

Today's Range: $1.34
▼
$1.44
50-Day Range: $1.22
▼
$2.40
52-Week Range: $1.17
▼
$13.85

Volume: 445,210 shs
Average Volume: 411,934 shs
Market Capitalization: $74.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.80

G1 Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 719.4% Upside
$11.80 Price Target
Short Interest: Healthy
5.60% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.45
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$10,866 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.92) to ($0.89) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

327th out of 972 stocks

Pharmaceutical Preparations Industry

134th out of 445 stocks

3.4

Analyst's Opinion

Consensus Rating
G1 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.80, G1 Therapeutics has a forecasted upside of 719.4% from its current price of $1.44.
Amount of Analyst Coverage
G1 Therapeutics has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
5.60% of the outstanding shares of G1 Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
G1 Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in G1 Therapeutics has recently decreased by 1.02%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
G1 Therapeutics does not currently pay a dividend.
Dividend Growth
G1 Therapeutics does not have a long track record of dividend growth.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
G1 Therapeutics has received a 49.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Detoxifying agents for antineoplastic treatment (V03AF)" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for G1 Therapeutics is -2.45.

2.7

News and Social Media Coverage

News Sentiment
G1 Therapeutics has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for G1 Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 51 people have searched for GTHX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added G1 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, G1 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,866.00 in company stock.
Percentage Held by Insiders
Only 8.23% of the stock of G1 Therapeutics is held by insiders.
Percentage Held by Institutions
Only 30.04% of the stock of G1 Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for G1 Therapeutics are expected to grow in the coming year, from ($0.92) to ($0.89) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of G1 Therapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of G1 Therapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
G1 Therapeutics has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About G1 Therapeutics (NASDAQ:GTHX) Stock

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

GTHX Price History

30 days | 90 days | 365 days | Advanced Chart

GTHX Stock News Headlines

September 21, 2023 | americanbankingnews.com

G1 Therapeutics, Inc. (NASDAQ:GTHX) Receives Average Recommendation of "Moderate Buy" from Analysts

September 5, 2023 | finance.yahoo.com

G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

October 1, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

August 4, 2023 | msn.com

Wedbush Reiterates G1 Therapeutics (GTHX) Outperform Recommendation

August 3, 2023 | msn.com

Needham Maintains G1 Therapeutics (GTHX) Buy Recommendation

August 2, 2023 | finance.yahoo.com

G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights

August 1, 2023 | markets.businessinsider.com

G1 Therapeutics earnings: here's what Wall Street expects

July 31, 2023 | finance.yahoo.com

G1 Therapeutics to Participate in Two August Investor Conferences

October 1, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

July 31, 2023 | finance.yahoo.com

New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

July 27, 2023 | finance.yahoo.com

G1 Therapeutics, Inc.'s (NASDAQ:GTHX) top owners are individual investors with 46% stake, while 38% is held by institutions

July 26, 2023 | finance.yahoo.com

G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023

June 26, 2023 | markets.businessinsider.com

Where G1 Therapeutics Stands With Analysts

June 26, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for G1 Therapeutics (GTHX)

June 5, 2023 | markets.businessinsider.com

BTIG Keeps Their Buy Rating on G1 Therapeutics (GTHX)

June 4, 2023 | finance.yahoo.com

G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Path To Profitability

June 4, 2023 | finance.yahoo.com

Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy

May 22, 2023 | finance.yahoo.com

G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel

May 16, 2023 | finance.yahoo.com

New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer

May 10, 2023 | markets.businessinsider.com

BTIG Sticks to Its Buy Rating for G1 Therapeutics (GTHX)

May 10, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on G1 Therapeutics (GTHX)

May 10, 2023 | msn.com

G1 Therapeutics trilaciclib cuts adverse events linked to Trodelvy in breast cancer patients

May 10, 2023 | finance.yahoo.com

New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)

May 8, 2023 | finance.yahoo.com

Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

May 5, 2023 | finance.yahoo.com

G1 Therapeutics First Quarter 2023 Earnings: Beats Expectations

May 4, 2023 | msn.com

Raymond James Maintains G1 Therapeutics (GTHX) Outperform Recommendation

May 4, 2023 | msn.com

HC Wainwright & Co. Reiterates G1 Therapeutics (GTHX) Buy Recommendation

See More Headlines

Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GTHX Company Calendar

Last Earnings: 8/02/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GTHX
CUSIP: N/A
CIK: 1560241
Web: www.g1therapeutics.com
Phone: (919) 213-9835
Fax: 919-741-5830
Employees: 170
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.80
High Stock Price Forecast: $19.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +719.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.71)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-147,560,000.00
Net Margins: -87.26%
Pretax Margin: -83.89%
Return on Equity: -143.26%
Return on Assets: -46.84%

Debt

Debt-to-Equity Ratio: 0.89
Current Ratio: 4.14
Quick Ratio: 3.68

Sales & Book Value

Annual Sales: $51.30 million
Price / Sales: 1.45
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.60 per share
Price / Book: 0.90

Miscellaneous

Outstanding Shares: 51,750,000
Free Float: 47,487,000
Market Cap: $74.52 million
Optionable: Optionable
Beta: 1.87

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. John E. Bailey Jr. (Age 58)
CEO, Pres & Director
Comp: $1.06M

Dr. Mark A. Velleca M.D. (Age 59)
Ph.D., Sr. Advisor & Director
Comp: $245k

Mr. Mark Avagliano (Age 47)
Chief Bus. Officer
Comp: $628.54k

Mr. John W. Umstead V (Age 38)
Chief Financial Officer

Mr. Terry L. Murdock (Age 63)
Chief Operating Officer

Mr. William C. Roberts (Age 54)
VP of Investor Relations & Corp. Communications

Mr. Alexander D. Smith M.S.
VP of Technical Operations

Ms. Monica R. Thomas
Gen. Counsel & Chief Compliance Officer

Dr. Jay C. Strum Ph.D. (Age 59)
Chief Scientific Officer

Mr. Evan Hicks M.B.A.
VP of Marketing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GTHX Stock - Frequently Asked Questions

Should I buy or sell G1 Therapeutics stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GTHX shares.
View GTHX analyst ratings or view top-rated stocks.
What is G1 Therapeutics' stock price forecast for 2023?: 6 Wall Street analysts have issued 1-year price objectives for G1 Therapeutics' shares. Their GTHX share price forecasts range from $5.00 to $19.00. On average, they anticipate the company's stock price to reach $11.80 in the next twelve months. This suggests a possible upside of 719.4% from the stock's current price.
View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts.
How have GTHX shares performed in 2023?: G1 Therapeutics' stock was trading at $5.43 at the beginning of 2023. Since then, GTHX stock has decreased by 73.5% and is now trading at $1.44.
View the best growth stocks for 2023 here.
When is G1 Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our GTHX earnings forecast.
How were G1 Therapeutics' earnings last quarter?: G1 Therapeutics, Inc. (NASDAQ:GTHX) released its quarterly earnings results on Wednesday, August, 2nd. The company reported $0.14 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.31. The company earned $42.39 million during the quarter, compared to the consensus estimate of $28.34 million. G1 Therapeutics had a negative net margin of 87.26% and a negative trailing twelve-month return on equity of 143.26%.
What other stocks do shareholders of G1 Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?: (GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.
What is G1 Therapeutics' stock symbol?: G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."
How do I buy shares of G1 Therapeutics?: Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is G1 Therapeutics' stock price today?: One share of GTHX stock can currently be purchased for approximately $1.44.
How much money does G1 Therapeutics make?: G1 Therapeutics (NASDAQ:GTHX) has a market capitalization of $74.52 million and generates $51.30 million in revenue each year. The company earns $-147,560,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.
How many employees does G1 Therapeutics have?: The company employs 170 workers across the globe.
How can I contact G1 Therapeutics?: G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The official website for the company is www.g1therapeutics.com. The company can be reached via phone at (919) 213-9835, via email at jmacdonald@g1therapeutics.com, or via fax at 919-741-5830.

This page (NASDAQ:GTHX) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial